Argus upgraded Roche (RHHBY) to Buy from Hold with a $55 price target The firm is positive on the company’s strong line-up of blockbuster products, a sizable pipeline of new product candidates, rising margins, and a longstanding, growing dividend, the analyst tells investors in a research note. Following a strong run from August 2025 through February 2026, Roche shares have since retreated, falling about 17% since that time and providing an attractive entry-point for investors, Argus added.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RHHBY:
- White House says imposing tariffs on patented pharmaceutical products
- Trump Trade: President says Iran war will still take weeks
- Trump administration readying new pharmaceutical tariffs, FT reports
- VYMI vs. VIG vs. VYM: Which Vanguard Dividend ETF Pays You Most?
- Trump Trade: U.S. not pulling assets from Strait of Hormuz yet